{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:09:35Z","timestamp":1792195775394,"version":"4.4.0"},"reference-count":121,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Overall outcomes for multiple myeloma have improved due to the availability of new therapies, but patients with relapsed\/refractory multiple myeloma harbouring certain factors continue to pose a therapeutic challenge. These challenging features include high\u2010risk cytogenetics, renal impairment, patient characteristics such as age and frailty, and extramedullary disease. Prior refractory status and number of prior lines add further complexity to the treatment of these patients. While newer regimens are available and have suggested efficacy in these patient populations through subgroup analyses, differences in trial definitions and cut\u2010offs make meaningful comparisons difficult. This review aims to examine the available clinical trial data for patients with high\u2010risk cytogenetics, renal impairment, age and frailty and extramedullary disease.<\/jats:p>","DOI":"10.1002\/jha2.743","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T04:41:28Z","timestamp":1691037688000},"page":"1117-1131","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Difficult\u2010to\u2010treat patients with relapsed\/refractory multiple myeloma: A review of clinical trial results"],"prefix":"10.1002","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4181-6922","authenticated-orcid":false,"given":"Marc S.","family":"Raab","sequence":"first","affiliation":[{"name":"Heidelberg Myeloma Center, Department of Medicine V University Hospital Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[{"name":"Seragnoli Institute of Hematology Bologna University School of Medicine Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hospital Center of Lille Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-7785","authenticated-orcid":false,"given":"Paula","family":"Rodriguez\u2010Otero","sequence":"additional","affiliation":[{"name":"Department of Hematology Clinica Universidad de Navarra Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-0569","authenticated-orcid":false,"given":"Fredrik","family":"Schjesvold","sequence":"additional","affiliation":[{"name":"Oslo Myeloma Center, Department of Haematology Oslo University Hospital, Oslo, Norway, and KG Jebsen Center for B Cell Malignancies University of Oslo Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0554-8003","authenticated-orcid":false,"given":"Annemiek","family":"Broijl","sequence":"additional","affiliation":[{"name":"Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.307"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30756-7"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.329"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15680"},{"key":"e_1_2_12_7_1","volume-title":"Real\u2010world prescribing patterns in U.S. multiple myeloma (MM) patients refractory to lenalidomide in the front\u2010line","author":"Raju MRD","year":"2016"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000846468.64341.f1"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615187"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.099358"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390658"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00643-3"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246322"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.2598"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020336"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016212"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009910"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.74.12.5729"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1983427"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-295105"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0307-4"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.8044"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.03.005"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-62885-0"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17499"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00474-8"},{"key":"e_1_2_12_28_1","unstructured":"International MyelomaFoundation.International Myeloma Working Group (IMWG) molecular classification of multiple myeloma. Available from:https:\/\/www.myeloma.org\/resource\u2010library\/international\u2010myeloma\u2010working\u2010group\u2010imwg\u2010molecular\u2010classification\u2010multiple\u2010myeloma. Accessed 26 Sep 2022."},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.01.003"},{"key":"e_1_2_12_30_1","unstructured":"NCCN.NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): multiple myeloma.Plymouth Meeting PA USA:NCCN;2022."},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02614"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00776"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00638-0"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00592-4"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00128-5"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30734-0"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00375-2"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00948-5"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13706"},{"key":"e_1_2_12_42_1","unstructured":"RichardS.Once weekly selinexor bortezomib and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma: high\u2010risk cytogenetic risk planned subgroup analyses from the phase 3 Boston Study. In:62nd ASH Annual Meeting and Exposition; December 5\u20138 2020; Virtual."},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-791228"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-6367(21)00094-4"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.92"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2576"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8541"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33809"},{"key":"e_1_2_12_49_1","unstructured":"JakubowiakA.Efficacy and safety of ciltacabtagene autoleucel in patients with relapsed\/refractory multiple myeloma: CARTITUDE\u20101 subgroup analysis. In:ASH Annual Meeting and Exposition. December 11\u201314 2021; Atalanta GA."},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002827"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011101"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00860"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e19280"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01814"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.0044"},{"key":"e_1_2_12_57_1","unstructured":"RakshitS.Factors associated with renal impairment at diagnosis in multiple myeloma with survival trends over last two decades. In:ASH Annual Meeting & Exposition. December 11\u201314 2021; Atalanta GA."},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23416"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101819"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2016.1210003"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2017.09.007"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.49"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-860015"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0868-z"},{"key":"e_1_2_12_65_1","unstructured":"CapraM.Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: Ikema subgroup analysis. In:62nd ASH Annual Meeting and Exposition. December 5\u20138 2020; Virtual."},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279229"},{"key":"e_1_2_12_67_1","doi-asserted-by":"crossref","unstructured":"SchjesvoldF DimopoulosM BeksacM.Pomalidomide bortezomib dexamethasone after 1 prior line of therapy in patients with relapsed or refractory multiple myeloma and renal impairment: OPTIMISMM subanalysis. In: European Association of Hematology Annual Meeting 2020; June 11\u201321 2020; Virtual.","DOI":"10.1016\/j.htct.2020.10.454"},{"key":"e_1_2_12_68_1","unstructured":"Janssen.Darzalex Prescribing Information.Horsham PA:Janssen Biotech Inc.;2022."},{"key":"e_1_2_12_69_1","unstructured":"Administration UFaD.Sarclisa Prescribing Information.Bridgewater NJ:Sanofi\u2010aventis U.S. LLC;2020."},{"key":"e_1_2_12_70_1","unstructured":"Myers\u2010SquibbB.Empliciti Prescribing Information.Princeton NJ:Bristol Myers\u2010Squibb Company;2022."},{"key":"e_1_2_12_71_1","unstructured":"Takeda.Ninlaro Prescribing Information.Cambridge MA:Takeda Pharmaceutical Company Limited;2022."},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0110-7"},{"key":"e_1_2_12_73_1","unstructured":"SEER.Cancer stat facts: myeloma. Accessed June 2022. Available from:https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed 20 Jun 2022."},{"key":"e_1_2_12_74_1","first-page":"423","article-title":"Multiple myeloma in the very elderly patient: challenges and solutions","volume":"11","author":"Willan J","year":"2016","journal-title":"Clin Interv Aging"},{"key":"e_1_2_12_75_1","article-title":"Survival trends in elderly myeloma patients","author":"Jones A","year":"2020","journal-title":"Eur J Haematol"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01488-8"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.173617"},{"key":"e_1_2_12_78_1","doi-asserted-by":"crossref","unstructured":"BerdejaJG.Efficacy and safety of idecabtagene vicleucel (ide\u2010cel bb2121) in elderly patients with relapsed and refractory multiple myeloma: KarMMa subgroup analysis.62nd ASH Annual Meeting2020.","DOI":"10.1182\/blood-2020-134322"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009507"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03143"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.217448"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.253450"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124349"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8026"},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13706"},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00432-4"},{"key":"e_1_2_12_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17338"},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.094409"},{"key":"e_1_2_12_89_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.178434"},{"key":"e_1_2_12_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00956.x"},{"key":"e_1_2_12_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2484-y"},{"key":"e_1_2_12_92_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.9961"},{"key":"e_1_2_12_93_1","unstructured":"BeksacM.2289 Isatuximab plus Pomalidomide and Dexamethasone in patients with relapsed\/refractory multiple Myeloma and soft\u2010tissue Plasmacytomas: Icaria\u2010MM subgroup analysis.ASH Annual Meeting (Virtual);2020."},{"key":"e_1_2_12_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)02323-5"},{"key":"e_1_2_12_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_2_12_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129038"},{"key":"e_1_2_12_97_1","unstructured":"MoreauP.Updated results from MajesTEC\u20101: Phase 1\/2 study of teclistamab a b\u2010cell maturation antigen x cd3 bispeci.ASH Annual Meeting;2020."},{"key":"e_1_2_12_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00019-5"},{"key":"e_1_2_12_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13835"},{"key":"e_1_2_12_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.04.013"},{"key":"e_1_2_12_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4"},{"key":"e_1_2_12_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32292-3"},{"key":"e_1_2_12_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18233"},{"key":"e_1_2_12_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00579-9"},{"key":"e_1_2_12_105_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_2_12_106_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_2_12_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"e_1_2_12_108_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26434"},{"key":"e_1_2_12_109_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_2_12_110_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0711-6"},{"key":"e_1_2_12_111_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"e_1_2_12_112_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14549"},{"key":"e_1_2_12_113_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1298755"},{"key":"e_1_2_12_114_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0300-y"},{"key":"e_1_2_12_115_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26319"},{"key":"e_1_2_12_116_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001965"},{"key":"e_1_2_12_117_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02096"},{"key":"e_1_2_12_118_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000229"},{"key":"e_1_2_12_119_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008733"},{"key":"e_1_2_12_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101465"},{"key":"e_1_2_12_121_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000346"},{"key":"e_1_2_12_122_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017635"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.743","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T18:50:33Z","timestamp":1700679033000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,2]]},"references-count":121,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1002\/jha2.743"],"URL":"https:\/\/doi.org\/10.1002\/jha2.743","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,2]]},"assertion":[{"value":"2023-01-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}